BioMarin survey shows strong Vimizim demand, says Leerink Leerink said its survey of 14 physicians indicates "robust" demand and early commercial adoption of BioMarin's Vimizim. The firm believes physicians and patients are less critical of Vimizim's clinical profile than Wall Street. It reiterates an Outperform rating on BioMarin shares with a $90 price target.
BioMarin upgraded to Buy from Neutral at Goldman Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.